![](https://endpts.com/wp-content/uploads/2021/09/Marc-Dunoyer-AstraZeneca-2.jpg)
Marc Dunoyer, Alexion CEO
AstraZeneca wagers on $500M buyout, plucks PhIII drug for Alexion’s rare disease pipeline — and jumps straight into risky field
Marc Dunoyer has unveiled his first buyout since taking over at Alexion — one that his predecessors have lassoed in before a $39 billion merger made …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.